Medical/Pharmaceuticals
Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities
SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader and more diverse therapeutic landscape. Viva Biotech has responded by building an integrated pharmacology pl...
2025-12-29 14:13
132
Alphamab Oncology Announces IND Application for a Phase II Clinical Study of HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 as First-line Treatment of Advanced Cervical Cancer was Officially Accepted by CDE
SUZHOU, China, Dec. 29, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immu...
2025-12-29 13:52
338
Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC "Blockbuster" Therapy
TAIPEI and SAN DIEGO, Dec. 28, 2025 /PRNewswire/ -- Following its recent clinical collaboration with the multinational pharmaceutical company BeOne Medicines to explore combination therapy with its marketed PD-1 inhibitor in the challenging field of cold tumor treatment, Senhwa Biosciences, Inc. ...
2025-12-29 10:24
375
Assure Healthcare Holdings Opens Second Clinic in Woodlands, Singapore
SINGAPORE, Dec. 29, 2025 /PRNewswire/ -- Assure Healthcare Holdings, a subsidiary of SingWealth Holdings, today announced the official opening of its second clinic,Assure Family Clinic Woodlands. This expansion marks the next phase in the Group's mission to make quality and comprehensive healthca...
2025-12-29 10:00
225
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Dec. 28, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it has entered into a l...
2025-12-29 09:58
297
CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596
SHANGHAI, Dec. 28, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submitted two separate Investigational New Drug (IND) applications to the National Medical Products Administr...
2025-12-29 08:10
192
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
- Secured a total of 55 million in R&D funding, including 40 million in upfront payment and 15 million in equity investment - Accelerating R&D on core technologies, including expansion of indications for the Grabody platform SEOUL, South Korea, Dec. 26, 2025 /PRNewswire/ -- ABL Bio (CEO Sang Ho...
2025-12-26 12:55
1171
China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval
* TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment of patients with stage IIB-III resectable microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) colon cancer. * The TABOSUN® and TYVYT® c...
2025-12-25 16:45
743
Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies
* Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 for weight management (CBL-0201WR Phase 2). * The study will evaluate CBL-514 in combination with Zepbound® (Eli Lilly) in...
2025-12-25 10:05
627
Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026
SYDNEY, Dec. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the acceptance of an ...
2025-12-24 22:02
602
Mabwell Receives IND Clearance for Novel Anti-ST2 Monoclonal Antibody 9MW1911 to Initiate Phase IIa Study
SHANGHAI, Dec. 24, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance from the U.S. Food and Drug Administration (FDA) for its self-developed anti-ST2 monoclonal antibody (R&...
2025-12-24 22:00
733
HKSH Medical Group Signed Memorandum of Understanding with Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen To Advance Precision Proton Therapy, Furthering the Healthy China Initiative
HONG KONG, Dec. 24, 2025 /PRNewswire/ -- In alignment with the national framework for the advancement of proton therapy, facilitated by the National Cancer Center, HKSH Medical Group ("HKSH") and Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen ("Shenzhen Cancer Hospital") signed a me...
2025-12-24 15:49
1011
Hakka Medicine Goes Global: Jiaying Pharmaceutical Launches the Global Promotion Plan for Hakka Medicine in Hong Kong
HONG KONG, Dec. 24, 2025 /PRNewswire/ -- Recently, Guangdong Jiaying Pharmaceutical Co., Ltd. held the "First Hakka Medicine Historical and Cultural Symposium" and the "Jiaying Hakka Medicine - Double-ingredient Throat Wind Relief Powder Product Promotion Conference" inHong Kong SAR. Centered on ...
2025-12-24 10:00
1076
Nona Biosciences Expands Integrated Discovery-to-Clinical Capabilities Through Strategic Platform Growth
CAMBRIDGE, Mass., Dec. 23, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the expansion of its integrated discovery and development framework to support early clinical development an...
2025-12-24 09:20
1135
Bridging the "Last Mile" of Medical Innovation: ICMIS 2025 Successfully Concludes with Capital and Industry Collaborating to Accelerate Commercialization
HONG KONG, Dec. 23, 2025 /PRNewswire/ -- In the current global MedTech landscape, technological breakthroughs are only the starting point. The real measure of scientific research is whether laboratory discoveries can be translated into safe, effective, and widely used clinical products. Yet the ...
2025-12-23 23:03
2271
Senhwa Biosciences Highlights AI-Validated Oncology Platform and Strategic Clinical Collaborations Targeting Next-Generation Immuno-Oncology products at Its 2025 Annual Investor Conference
TAIPEI and SAN DIEGO, Dec. 23, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage companies focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today outlined continued progress across its AI-enabled drug developm...
2025-12-23 20:00
2121
Fapon Biopharma Publishes Pioneering Research in Cell Reports Medicine on FP008, an anti-PD 1 X IL-10M Fusion Protein for Cancer Immunotherapy
DONGGUAN, China, Dec. 23, 2025 /PRNewswire/ -- Fapon Biopharma, a biotech in developing therapeutic biologics including cytokine-antibody fusion proteins and T-cell engagers, announced the publication of pioneering research on FP008, a novel fusion protein inCell Reports Medicine. The peer-review...
2025-12-23 13:03
2204
TraceLink Wins 2025 Merit Award -- Recognized for Healthcare Innovation for the Third Consecutive Year
TraceLink has been named a winner of the 2025 Merit Awards for Healthcare Innovation, marking its third consecutive year of recognition. The award honors TraceLink's continued leadership in transforming the life sciences and healthcare supply chain through OPUS—its industrial no-code platform tha...
2025-12-22 23:00
1869
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength SYDNEY, Dec. 22, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") (NASDAQ: KZIA), a clinical-stage oncology company focused on developing innovative therap...
2025-12-22 21:00
2851
Guardant Health Japan receives regulatory approval of Guardant360® CDx liquid biopsy as companion diagnostic for imlunestrant in metastatic or recurrent breast cancer previously treated with endocrine therapy
Guardant360® CDx is the first companion diagnostic to be approved in Japan to identify ESR1 mutations in patients with hormone receptor-positive, HER2-negative breast cancer for treatment with imlunestrant TOKYO, Dec. 22, 2025 /PRNewswire/ -- Guardant Health Japan Corp. today announced that the...
2025-12-22 16:00
2040
Week's Top Stories
Most Reposted
Nine Years of Impact: JULO Disburses USD 1.7 Billion in Digital Financing Across Indonesia
[Picked up by 297 media titles]
2025-12-23 14:23
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 277 media titles]
2025-12-26 12:55Fijian and Chinese Scholars Gather to Discuss Bilateral Friendship and the Outlook for APEC 2026
[Picked up by 264 media titles]
2025-12-22 15:56
"Nihao China" App Launches as an All-in-One Solution for International Visitors
[Picked up by 253 media titles]
2025-12-24 17:54Sobot Shines in G2 Winter 2026: A New Benchmark in AI Customer Service
[Picked up by 252 media titles]
2025-12-24 10:00